Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer : Subgroup analysis of the randomised phase III AURELIA trial

•The PFS and response rate benefit from bevacizumab were similar regardless of age.•Grade≥3 hypertension was more common with bevacizumab in older vs younger patients.•Thromboembolic events were not increased with bevacizumab in patients ≥65 vs <65years.•In older patients, no PRO benefit was seen with bevacizumab versus chemotherapy alone.